2/18
07:00 am
kalv
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Low
Report
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
2/17
09:36 am
kalv
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
Low
Report
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
2/12
07:16 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
2/12
07:00 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/11
03:46 pm
kalv
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
Low
Report
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
2/3
07:00 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
03:51 pm
kalv
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
Low
Report
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
1/24
05:09 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
08:02 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
1/8
04:27 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
1/8
04:05 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
1/6
08:00 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
12/22
06:00 am
kalv
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
Low
Report
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
12/4
08:05 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
High
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
12/3
03:13 pm
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.